Search hospitals
>
California
>
Los Angeles
Children's Hospital Los Angeles
Claim this profile
Los Angeles, California 90027
Global Leader in Brain Tumor
Global Leader in Cancer
Conducts research for Neuroblastoma
Conducts research for Acute Lymphoblastic Leukemia
Conducts research for Solid Tumors
1022 reported clinical trials
64 medical researchers
Summary
Children's Hospital Los Angeles is a medical facility located in Los Angeles, California. This center is recognized for care of Brain Tumor, Cancer, Neuroblastoma, Acute Lymphoblastic Leukemia, Solid Tumors and other specialties. Children's Hospital Los Angeles is involved with conducting 1,022 clinical trials across 1,266 conditions. There are 64 research doctors associated with this hospital, such as Leo Mascarenhas, MD, Fariba Navid, MD, Nathan Robison, MD, and Michael Pulsipher, MD.
Area of expertise
Brain Tumor
Children's Hospital Los Angeles has run 100 trials for Brain Tumor. Some of their research focus areas include:
Cancer
Children's Hospital Los Angeles has run 100 trials for Cancer. Some of their research focus areas include:
Top PIs
Leo Mascarenhas, MD
Children's Hospital Los Angeles
5 years of reported clinical research
Fariba Navid, MD
Children's Hospital Los Angeles
3 years of reported clinical research
Nathan Robison, MD
Children's Hospital Los Angeles
6 years of reported clinical research
Michael Pulsipher, MD
Children's Hospital Los Angeles
6 years of reported clinical research
Clinical Trials running at Children's Hospital Los Angeles
Neuroblastoma
Brain Tumor
Acute Lymphoblastic Leukemia
Testicular cancer
Hemophilia B
Burkitt Lymphoma
Leukemia
Bone Cancer
Autism Spectrum Disorder
Hemophilia
Dinutuximab + Chemotherapy
for High-Risk Neuroblastoma
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.
Recruiting
2 awards
Phase 3
7 criteria
Lorlatinib + Standard Therapy
for Neuroblastoma
This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Lorlatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or lorlatinib and standard therapy may work better compared to lorlatinib and standard therapy alone in treating younger patients with neuroblastoma or ganglioneuroblastoma.
Recruiting
2 awards
Phase 3
22 criteria
Biology Study
for Neuroblastoma
Medical scientists want to find better ways to treat neuroblastoma and to find ways to prevent the tumor from growing back. To do this, they need more information about the characteristics of neuroblastoma cells. Therefore, they want to study samples of neuroblastoma tissues and neuroblastoma and normal cells in the blood and bone marrow that may be related to the growth of neuroblastoma cells. Doctors and other medical scientists also want to find better ways to detect and measure neuroblastoma to improve the ability to follow the response of tumor cells to therapy.
Recruiting
1 award
N/A
4 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Children's Hospital Los Angeles?
Children's Hospital Los Angeles is a medical facility located in Los Angeles, California. This center is recognized for care of Brain Tumor, Cancer, Neuroblastoma, Acute Lymphoblastic Leukemia, Solid Tumors and other specialties. Children's Hospital Los Angeles is involved with conducting 1,022 clinical trials across 1,266 conditions. There are 64 research doctors associated with this hospital, such as Leo Mascarenhas, MD, Fariba Navid, MD, Nathan Robison, MD, and Michael Pulsipher, MD.
Where is Children's Hospital Los Angeles located?
Children's Hospital Los Angeles is situated at 4650 W Sunset Blvd, Hollywood, California. It is easily accessible from the I-5 Freeway (exit Los Feliz Boulevard) and Highway 101. Public transportation options include MTA bus stops directly in front of the hospital.
Who should I call to ask about financial aid or insurance network?
### Children's Hospital Los Angeles Financial Assistance and Insurance Contact Information **Financial Assistance:** - **Address:** Patient Business Services, Mailstop 26, Children's Hospital Los Angeles, 4650 Sunset Boulevard, Los Angeles, California 90027 - **Phone:** (800) 404-6627 - **Application Submission:** CHLA’s Admitting Department, in person or by mail - **Application Assistance:** Health Consumer Center of Los Angeles, 13327 Van Nuys Boulevard, Pacoima, CA 91331, Phone: (800) 896-3203 **Insurance:** - **Hospital Bill Inquiries and Payments:** Call 323-361-2515 - **Physician Bill Inquiries and Payments:** Children's Hospital Los Angeles Medical Group, Call 323-361-2336
What insurance does Children's Hospital Los Angeles accept?
Children's Hospital Los Angeles accepts most insurance plans, including Medicaid and most private health plans. The specific insurance plans accepted may vary by the services provided and care location. For confirmation on in-network status, contact the hospital directly or consult with your insurance provider. Financial assistance programs are available for those unable to afford their hospital bill due to lack of insurance or high medical expenses.
What awards or recognition has Children's Hospital Los Angeles received?
Children's Hospital Los Angeles (CHLA) is distinguished by its significant funding for research and care, ranking among the top U.S. pediatric hospitals for National Institutes of Health (NIH) grant funding. It holds the American Nurses Credentialing Center Magnet Recognition®, a prestigious distinction shared by only 100 Great Hospitals in America. Additionally, CHLA's participation in prestigious research consortia offers patients early access to innovative treatments through clinical trials.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.